"The Report
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator
Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Global Markets Directs,
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator
Inhibitor or Serpin E1 or PAI-1)
- Pipeline Review, H1 2016, provides in depth analysis on Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) targeted pipeline therapeutics.
The report provides
comprehensive information on the Plasminogen Activator Inhibitor-1
(Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1),
targeted therapeutics, complete with analysis by indications, stage
of development, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator
Inhibitor or Serpin E1 or PAI-1) targeted therapeutics development
and features dormant and discontinued projects.
Global Markets Directs report
features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Drug profiles featured in the report undergoes
periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
The report helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen
Activator Inhibitor or Serpin E1 or PAI-1)
-
The report reviews Plasminogen Activator Inhibitor-1 (Endothelial
Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and
industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Plasminogen Activator
Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1
or PAI-1) targeted therapeutics and enlists all their major and minor
projects
-
The report assesses Plasminogen Activator Inhibitor-1 (Endothelial
Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted
therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) targeted therapeutics
Reasons to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen
Activator Inhibitor or Serpin E1 or PAI-1)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator
Inhibitor or Serpin E1 or PAI-1) development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
List
of Tables 5
List
of Figures 5
Introduction
6
Global
Markets Direct Report Coverage 6
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) Overview 7
Therapeutics
Development 8
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Products under Development by Stage of
Development 8
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Products under Development by Therapy Area 9
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Products under Development by Indication 10
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Pipeline Products Glance 12
Late
Stage Products 12
Early
Stage Products 13
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Products under Development by Companies 14
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Products under Development by
Universities/Institutes 16
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Therapeutics Assessment 18
Assessment
by Monotherapy/Combination Products 18
Assessment
by Mechanism of Action 19
Assessment
by Route of Administration 21
Assessment
by Molecule Type 23
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Companies Involved in Therapeutics Development
25
D-Pharm
Ltd. 25
Jazz
Pharmaceuticals Plc 26
Plasminogen
Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or
Serpin E1 or PAI-1) - Drug Profiles 27
CT-140
- Drug Profile 27
Product
Description 27
Mechanism
Of Action 27
R&D
Progress 27
defibrotide
sodium - Drug Profile 28
Product
Description 28
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment